PTGS2 and colorectal carcinoma: Erythromycin has the ability to suppress the transcriptional activity of NF-κB and the activator protein-1 (AP-1), as well as its downstream targets, IL-6 and cyclooxygenase-2 (COX-2), in human CRC cells.